Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery

Urologia Internationalis

Volumn 87, Issue 1, 2011, Pages 42-48

  Nuhn, Philipp ^a   Bastian, Patrick J ^a,b   Novara, Giacomo ^c   Svatek, Robert S ^d   Karakiewicz, Pierre I ^e   Skinner, Eila ^f   Fradet, Yves ^g   Izawa, Jonathan I ^h   Kassouf, Wassim ⁱ   Montorsi, Francesco ^j   Müller, Stefan C ^b   Fritsche, Hans Martin ^k   Sonpavde, Guru ^l   Tilki, Derya ^a   Isbarn, Hendrik ^d   Ficarra, Vincenzo ^j   Dinney, Colin P ^d   Shariat, Shahrokh F ^m  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITÉ LAVAL   (Canada)

^h UNIVERSITY OF WESTERN ONTARIO   (Canada)

ⁱ MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^j VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^k UNIVERSITY OF REGENSBURG   (Germany)

^l BAYLOR COLLEGE OF MEDICINE   (United States)

^m WEILL CORNELL MEDICAL COLLEGE   (United States)

more..

Author keywords

Bladder cancer; Carcinoma in situ; Radical cystectomy, prognosis; Urothelial carcinoma, survival

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CARCINOMA IN SITU; CLINICAL DECISION MAKING; COMORBIDITY; CYSTECTOMY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOLOGIST; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA; CARCINOMA IN SITU; CHI-SQUARE DISTRIBUTION; CYSTECTOMY; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NORTH AMERICA; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM; YOUNG ADULT;

EID: 80051793091     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000325463     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Skinner DG, Richie JP, Cooper PH, Waisman J, Kaufman JJ: The clinical significance of carcinoma in situ of the bladder and its association with overt carcinoma. J Urol 1974; 112: 68-71.
3. Utz DC, Hanash KA, Farrow GM: The plight of the patient with carcinoma in situ of the bladder. J Urol 1970; 103: 160-164.
4. Lamm DL: Carcinoma in situ. Urol Clin North Am 1992; 19: 499-508.
5. Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, et al: Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 2007; 51: 152-160. (Pubitemid 44821530)
6. Shariat SF, Palapattu GS, Amiel GE, Karakiewicz PI, Rogers CG, Vazina A, et al: Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. Urology 2006; 68: 538-542. (Pubitemid 44436492)
7. Gupta A, Lotan Y, Bastian PJ, Palapattu GS, Karakiewicz PI, Raj GV, et al: Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology 2008; 71: 302-307. (Pubitemid 351282384)
8. Zincke H, Garbeff PJ, Beahrs JR: Upper urinary tract transitional cell cancer after radical cystectomy for bladder cancer. J Urol 1984; 131: 50-52. (Pubitemid 14218087)
9. Solsona E, Iborra I, Ricos JV, Dumont R, Casanova JL, Calabuig C: Upper urinary tract involvement in patients with bladder carcinoma in situ (Tis): Its impact on management. Urology 1997; 49: 347-352. (Pubitemid 27138674)
10. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Huguet-Perez J, Vicente-Rodriguez J: Upper urinary tract tumors after primary superficial bladder tumors: Prognostic factors and risk groups. J Urol 2000; 164: 1183-1187.
11. Nixon RG, Chang SS, Lafleur BJ, Smith JJ, Cookson MS: Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. J Urol 2002; 167: 502-505. (Pubitemid 34074515)
12. Kattan MW: Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003; 95: 634-635. (Pubitemid 36603708)
13. Shariat SF, Karakiewicz PI, Ashfaq R, Lerner SP, Palapattu GS, Cote RJ, et al: Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008; 112: 315-325.
14. Fine JP: Regression modeling of competing crude failure probabilities. Biostatistics 2001; 2: 85-97.
15. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA: Evaluating the yield of medical tests. JAMA 1982; 247: 2543-2546. (Pubitemid 12155954)
16. Harrell FE Jr, Lee KL, Mark DB: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387. (Pubitemid 26072233)
17. Habuchi T, Ogawa O, Kakehi Y, Ogura K, Koshiba M, Sugiyama T, et al: Allelic loss of chromosome 17p in urothelial cancer: Strong association with invasive phenotype. J Urol 1992; 148: 1595-1599.
18. Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, et al: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54: 784-788. (Pubitemid 24068337)
19. Rosin MP, Cairns P, Epstein JI, Schoenberg MP, Sidransky D: Partial allelotype of carcinoma in situ of the human bladder. Cancer Res 1995; 55: 5213-5216.
20. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG: Allelotype of human bladder cancer. Cancer Res 1994; 54: 531-538. (Pubitemid 24053197)
21. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K, et al: Gene expression in the urinary bladder: A common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004; 64: 4040-4048. (Pubitemid 38697320)
22. Sarkis AS, Dalbagni G, Cordon-Cardo C, Melamed J, Zhang ZF, Sheinfeld J, et al: Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994; 152: 388-392. (Pubitemid 24221226)
23. Shariat SF, Pahlavan S, Baseman AG, Brown RM, Green AE, Wheeler TM, et al: E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology 2001; 57: 60-65. (Pubitemid 32065821)
24. Shariat SF, Kim JH, Ayala GE, Kho K, Wheeler TM, Lerner SP: Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol 2003; 169: 938-942. (Pubitemid 36188129)
25. Shariat SF, Kim J, Raptidis G, Ayala GE, Lerner SP: Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 2003; 61: 1140-1155.
26. Masood S, Sriprasad S, Palmer JH, Mufti GR: T1G3 bladder cancer -indications for early cystectomy. Int Urol Nephrol 2004; 36: 41-44. (Pubitemid 38864807)
27. Vicente J, Laguna MP, Duarte D, Algaba F, Chechile G: Carcinoma in situ as a prognostic factor for G3pT1 bladder tumours. Br J Urol 1991; 68: 380-382.
28. Smits G, Schaafsma E, Kiemeney L, Caris C, Debruyne F, Witjes JA: Microstaging of pT1 transitional cell carcinoma of the bladder: Identification of subgroups with distinct risks of progression. Urology 1998; 52: 1009-1013.
29. Orsola A, Trias I, Raventos CX, Espanol I, Cecchini L, Bucar S, et al: Initial high-grade T1 urothelial cell carcinoma: Feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 2005; 48: 231-238. (Pubitemid 40957095)
30. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2,596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-465.